Stock RX BIOSYENT INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioSyent Inc.

Equities

RX

CA0906901081

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:50:43 2024-07-05 pm EDT 		5-day change 1st Jan Change
10 CAD +2.46% Intraday chart for BioSyent Inc. -3.57% +8.46%
May. 17 Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. CI
May. 17 BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 82.85 101.3 103.9 84.69 108.4 113.1 - -
Enterprise Value (EV) 1 82.85 101.3 103.9 84.69 108.4 113.1 113.1 113.1
P/E ratio 19.7 x 27.3 x 16.9 x 16.1 x 17.4 x 18.2 x 15.9 x 13.5 x
Yield - - - - - - - -
Capitalization / Revenue 3.87 x 4.54 x 3.63 x 3.03 x 3.43 x 3.23 x 2.92 x 2.66 x
EV / Revenue 3.87 x 4.54 x 3.63 x 3.03 x 3.43 x 3.23 x 2.92 x 2.66 x
EV / EBITDA 14.4 x 18.2 x 11.8 x 11.4 x 13.7 x 13.8 x 12.2 x 10.7 x
EV / FCF 20,522,435 x 15,072,496 x 22,679,224 x - - - - -
FCF Yield 0% 0% 0% - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 13,581 12,805 12,580 12,098 11,761 11,591 - -
Reference price 2 6.100 7.910 8.260 7.000 9.220 10.00 10.00 10.00
Announcement Date 3/18/20 3/17/21 3/9/22 3/21/23 3/13/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21.42 22.33 28.62 27.93 31.59 35 38.7 42.5
EBITDA 1 5.748 5.577 8.784 7.433 7.926 8.2 9.3 10.6
EBIT 5.388 5.03 8.183 - - - - -
Operating Margin 25.15% 22.52% 28.59% - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income - - - - - - - -
Net margin - - - - - - - -
EPS 2 0.3100 0.2900 0.4880 0.4350 0.5300 0.5500 0.6300 0.7400
Free Cash Flow 4.037 6.72 4.582 - - - - -
FCF margin 18.84% 30.09% 16.01% - - - - -
FCF Conversion (EBITDA) 70.23% 120.49% 52.16% - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/18/20 3/17/21 3/9/22 3/21/23 3/13/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 7.219 7.037 6.635 6.791 7.462 6.483 7.963 8.871 8.274 7.734 8.8 9 9.5
EBITDA 1 2.639 2.227 1.689 1.949 1.568 1.517 1.86 2.9 1.65 2.204 1.9 2 2.1
EBIT - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS 2 0.1470 0.1300 0.1000 0.1200 0.0970 0.1000 0.1200 0.2000 0.1200 0.1500 0.1300 0.1400 0.1500
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/9/22 5/18/22 8/23/22 11/17/22 3/21/23 5/26/23 8/22/23 11/16/23 3/13/24 5/16/24 - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 4.04 6.72 4.58 - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0.73 0.17 0.09 - - - - -
Capex / Sales 3.43% 0.78% 0.33% - - - - -
Announcement Date 3/18/20 3/17/21 3/9/22 3/21/23 3/13/24 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
10 CAD
Average target price
9.65 CAD
Spread / Average Target
-3.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BIOSYENT INC. Stock BioSyent Inc.
+8.46% 83.11M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 809B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 624B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 351B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 240B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 166B
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RX Stock
  4. Financials BioSyent Inc.